688321.SHG Shenzhen Chipscreen Biosciences Co
- Market cap
- CNY 9.39B
- P/E
- 124.6x
- P/B
- 3.43x
- ROE
- 4.8%
- Dividend yield
- 0.34%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688321.SHG undervalued?
Graham numberThe Graham number of Shenzhen Chipscreen Biosciences Co cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen Chipscreen Biosciences Co fundamental analysis
No fundamental analysis for Shenzhen Chipscreen Biosciences Co yet.
Shenzhen Chipscreen Biosciences Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the pharmaceutical industry in China. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma indications; Chiglitazar, a PPAR full agonist for diabetes treatment; Siglitazone for metabolism treatment area; and Cioronib, a novel molecular, which selectively inhibits tumor-related protein kinase targets. It is also inv…
Full company profileShenzhen Chipscreen Biosciences Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen Chipscreen Biosciences Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 85.4M | 111M | 148M | 174M | 269M | 430M | 530M | 524M | 658M | 910M | 1.12B |
| Gross Profit | 83.2M | 105M | 142M | 167M | 256M | 409M | 500M | 467M | 570M | 910M | 970M |
| Operating Income | 2.03M | 24.5M | 32.6M | 21.7M | 37.0M | 22.3M | 16.0M | 97.1M | -179M | 50.9M | 185M |
| EBITDA | 11.7M | 27.8M | 37.1M | 27.1M | 48.3M | 37.1M | 72.3M | 174M | -5.81M | 107M | 166M |
| Net Income | 5.24M | 24.1M | 31.2M | 19.4M | 31.0M | 22.0M | 17.5M | 88.8M | -115M | 51.1M | 122M |
| EPS | 0.02 | 0.07 | 0.09 | 0.05 | 0.08 | 0.05 | 0.04 | 0.22 | -0.28 | 0.13 | 0.27 |
| Balance Sheet | |||||||||||
| Total Assets | 403M | 656M | 716M | 1.69B | 1.73B | 1.89B | 2.90B | 3.20B | 3.25B | 3.65B | 4.49B |
| Total Liabilities | 190M | 205M | 239M | 245M | 232M | 477M | 1.32B | 1.49B | 1.67B | -1.66B | 1.94B |
| Shareholders' Equity | 213M | 451M | 477M | 1.45B | 1.49B | 1.42B | 1.52B | 1.59B | 1.58B | 1.66B | 2.55B |
| Cash & Short-term Investments | 109M | 103M | 131M | 380M | 581M | 382M | 800M | 850M | 469M | 636M | 706M |
| Total Debt | 30.0M | 75.0M | 87.5M | 105M | 60.0M | 151M | 810M | 1.04B | 1.20B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 59.8M | 2.73M | 22.8M | -24.6M | 93.6M | 125M | 43.3M | -143M | 76.1M | 97.0M | - |
| Capital Expenditure | 65.8M | 133M | 141M | 133M | 336M | 288M | 400M | 229M | 268M | 179M | 343M |
| Free Cash Flow | -6.04M | -130M | -118M | -158M | -243M | -164M | -357M | -386M | -192M | -81.6M | -179M |
| Ratios | |||||||||||
| ROE | 2.5% | 5.3% | 6.5% | 1.3% | 2.1% | 1.5% | 1.2% | 5.6% | -7.2% | 3.1% | 4.8% |
| ROA | 1.3% | 3.7% | 4.4% | 1.1% | 1.8% | 1.2% | 0.6% | 2.8% | -3.5% | 1.4% | 2.7% |
| Net Profit Margin | 6.1% | 21.8% | 21.1% | 11.2% | 11.5% | 5.1% | 3.3% | 17.0% | -17.4% | 5.6% | 10.8% |
| Debt to Equity | 0.14x | 0.17x | 0.18x | 0.07x | 0.04x | 0.11x | 0.53x | 0.66x | 0.76x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen Chipscreen Biosciences Co dividends
- Dividend yield
- 0.34%
- Forward dividend
- 0.06 CNY
- Payout ratio
- 62.1%
- Ex-dividend date
- May 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 31.7M | 0.08 | 62.1% |
| 2024 | CNY 27.6M | 0.07 | - |
| 2023 | CNY 18.7M | 0.05 | 21.1% |
| 2022 | CNY 12.2M | 0.03 | 69.6% |
| 2021 | CNY 4.22M | 0.01 | 19.2% |
| 2020 | CNY 3.28M | 0.01 | 10.6% |
| 2019 | CNY 1.48M | 0.00 | 7.6% |
| 2018 | CNY 550K | 0.00 | 1.8% |
| 2017 | CNY 2.32M | 0.01 | 9.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shenzhen Chipscreen Biosciences Co
- Insiders 25.39%
- Institutions 3.88%
- Public & others 70.72%
- Shares outstanding 443M
- Free float 315M
Shenzhen Chipscreen Biosciences Co company profile
- Company name
- Shenzhen Chipscreen Biosciences Co
- Ticker
- 688321.SHG
- ISIN
- CNE100003LW0
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,002
- Fiscal year end
- December
- Address
- Zhigu Industrial Park, Shenzhen, China, 518057
- Phone
- 86 755 2695 2070
- Website
- chipscreen.com
About Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the pharmaceutical industry in China. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma indications; Chiglitazar, a PPAR full agonist for diabetes treatment; Siglitazone for metabolism treatment area; and Cioronib, a novel molecular, which selectively inhibits tumor-related protein kinase targets. It is also involved in the development of CS23546, a small molecule PD-L1 inhibitor, which relieves the immunosuppressive activity mediated by the PD-1/PD-L1 signaling pathway; CS231295, a brain-penetrating selective Aurora B inhibitor; and CS32582, a small-molecule allosteric inhibitor of tyrosine kinase 2. In addition, the company develops CS08399, a potential brain-penetrating PRMT5-MTA inhibitor for BIC; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192, a highly selective JAK3 kinase inhibitor. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is headquartered in Shenzhen, China.
Shenzhen Chipscreen Biosciences Co management
9- Dr. Xian-Ping LuFounder & Chairman · born 1963
- Mr. Jian-Xun Li BA.CFAPresident, Head of Finance & Director · born 1971
- Dr. Leming ShiCo-Founder
- Dr. Desi PanVP, Deputy GM & Chief Scientific Officer · born 1971
- Dr. Zhi-Bin Li Ph.D.EVP, Deputy GM and Head of Product Development & Production · born 1965
- Ms. Ou HaiVP, Deputy GM, Secretary of the Board & Director · born 1978
- Dr. Weiming HuCo-Founder
- Mr. Ji-Hui Yi MSVice President of Sales & Marketing
- Mr. Liangji SheEVP, Deputy GM & Head of the Commercial Segment · born 1966